Paper1373166
Saponin adjuvant induction of ovalbumin-specific CD8+ cytotoxic T lymphocyte responses.
Newman MJ and 7 others. J Immunol, 1992. Cited by 192 papers, by iCite.
Cite this record
ConductScience Library. Saponin adjuvant induction of ovalbumin-specific CD8+ cytotoxic T lymphocyte responses. Papers, record 1373166. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/1373166
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics14
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Adjuvants, Immunologic | Major topic |
| CD8 Antigens | Major topic |
| Ovalbumin | Major topic |
| Saponins | Major topic |
| T-Lymphocytes, Cytotoxic | Major topic |
| Amino Acid Sequence | |
| Animals | |
| Epitopes | |
| Female | |
| Histocompatibility Antigens Class I | |
| Mice | |
| Mice, Inbred C57BL | |
| Molecular Sequence Data | |
| Phenotype |
Source PubMed
Cited by40
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 192 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42079571 | The challenge of one billion adjuvanted vaccine doses: evaluating scalability, sustainability, and supply capacity of Quillaja saponin QS-21 for large-scale vaccine demand. | Front Immunol | 2026 | https://conductscience.org/library/papers/42079571 | PubMed |
| 41409277 | From bark to bench: innovations in QS-21 adjuvant characterization and manufacturing. | Front Immunol | 2025 | https://conductscience.org/library/papers/41409277 | PubMed |
| 39083809 | Botensilimab, an Fc-Enhanced Anti-CTLA-4 Antibody, Is Effective against Tumors Poorly Responsive to Conventional Immunotherapy. | Cancer Discov | 2024 | https://conductscience.org/library/papers/39083809 | PubMed |
| 38750307 | A broadly applicable protein-polymer adjuvant system for antiviral vaccines. | EMBO Mol Med | 2024 | https://conductscience.org/library/papers/38750307 | PubMed |
| 37298177 | Progress towards Adjuvant Development: Focus on Antiviral Therapy. | Int J Mol Sci | 2023 | https://conductscience.org/library/papers/37298177 | PubMed |
| 37199661 | The Influence of Adjuvant Type on the Immunogenicity of RBD/N Cocktail Antigens as a Vaccine Candidate against SARS-CoV-2 Virus. | Microbiol Spectr | 2023 | https://conductscience.org/library/papers/37199661 | PubMed |
| 37020548 | Potentials of saponins-based adjuvants for nasal vaccines. | Front Immunol | 2023 | https://conductscience.org/library/papers/37020548 | PubMed |
| 36911719 | New-age vaccine adjuvants, their development, and future perspective. | Front Immunol | 2023 | https://conductscience.org/library/papers/36911719 | PubMed |
| 35979365 | Vaccine adjuvants to engage the cross-presentation pathway. | Front Immunol | 2022 | https://conductscience.org/library/papers/35979365 | PubMed |
| 34634664 | Generation of potent cellular and humoral immunity against SARS-CoV-2 antigens via conjugation to a polymeric glyco-adjuvant. | Biomaterials | 2021 | https://conductscience.org/library/papers/34634664 | PubMed |
| 33824489 | Emerging concepts in the science of vaccine adjuvants. | Nat Rev Drug Discov | 2021 | https://conductscience.org/library/papers/33824489 | PubMed |
| 33807582 | Natural and Synthetic Saponins as Vaccine Adjuvants. | Vaccines (Basel) | 2021 | https://conductscience.org/library/papers/33807582 | PubMed |
| 28105029 | Lysosome-Dependent Activation of Human Dendritic Cells by the Vaccine Adjuvant QS-21. | Front Immunol | 2016 | https://conductscience.org/library/papers/28105029 | PubMed |
| 27996000 | Central Role of CD169+ Lymph Node Resident Macrophages in the Adjuvanticity of the QS-21 Component of AS01. | Sci Rep | 2016 | https://conductscience.org/library/papers/27996000 | PubMed |
| 27014435 | Quillaja Saponin Variants with Central Glycosidic Linkage Modifications Exhibit Distinct Conformations and Adjuvant Activities. | Chem Sci | 2016 | https://conductscience.org/library/papers/27014435 | PubMed |
| 26344621 | Vaccine Potentiation by Combination Adjuvants. | Vaccines (Basel) | 2014 | https://conductscience.org/library/papers/26344621 | PubMed |
| 25932368 | The mechanisms of action of vaccines containing aluminum adjuvants: an in vitro vs in vivo paradigm. | Springerplus | 2015 | https://conductscience.org/library/papers/25932368 | PubMed |
| 21518876 | Vaccine adjuvants aluminum and monophosphoryl lipid A provide distinct signals to generate protective cytotoxic memory CD8 T cells. | Proc Natl Acad Sci U S A | 2011 | https://conductscience.org/library/papers/21518876 | PubMed |
| 18753338 | Primary CD8+ T-cell response to soluble ovalbumin is improved by chloroquine treatment in vivo. | Clin Vaccine Immunol | 2008 | https://conductscience.org/library/papers/18753338 | PubMed |
| 18053081 | The ginsenoside metabolite compound K, a novel agonist of glucocorticoid receptor, induces tolerance to endotoxin-induced lethal shock. | J Cell Mol Med | 2008 | https://conductscience.org/library/papers/18053081 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- References
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/1373166
GET https://conductscience.org/api/papers/v1/1373166/cited_by?page=2